Table 1.
Part of the baseline characteristics of the population included in each group
| Author | Nation | Year | Consecutive cases | Follow-up | Complete follow-up for 30-day | All patients | Age (years) | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ViV | ViR | ViMAC | ViV | ViR | ViMAC | ViV | ViR | ViMAC | ||||||
| Eleid [25] | US | 2017 | Yes | 30-day and 1-year | Yes | 60 | 15 | 12 | 75 ± 11 | 72 ± 8 | 79 ± 9 | 34 | 9 | 5 |
| Yoon [20] | US | 2018 | Yes | 1, 6, and 12 months and yearly thereafter | Yes | 322 | 141 | 58 | 72.6 ± 12.9 | 71.7 ± 9.7 | 74.7 ± 10.8 | 189 | 52 | 41 |
| Hu [26] | – | 2018 | NO | 1and 6 months | No | 172 | 73 | 74.5 ± 12.5 | 70.0 ± 10.8 | 61 | 21 | |||
| Tiwana [27] | US | 2020 | Yes | 30-day | Yes | 12 | 28 | 74.1(71.1–77.4) | 74.2(70–81.7) | 8 | 22 | |||
| Guerrero [28] | US | 2020 | unclear | 30-day | No | 680 | 123 | 100 | 76 (67–83) | 73 (67–79) | 77 (65–82.5) | 407 | 59 | 69 |
| Simonato [29] | US | 2020 | unclear |
492 days [IQR 76 – 996 days] |
YES | 857 | 222 | 74.1 ± 12.4 | 71.2 ± 12.8 | 530 | 109 | |||